Adaptimmune Therapeutics plc

ADAP · NASDAQ
Analyze with AI
6/30/2025
3/31/2025
12/31/2024
9/30/2024
Operating Activities
Net Income-$30-$48-$71-$18
Dep. & Amort.$3$2$3$3
Deferred Tax$0$0$0$0
Stock-Based Comp.$1$1$5$3
Change in WC-$8-$21$26-$46
Other Non-Cash-$1-$1$3$3
Operating Cash Flow-$35-$67-$34-$54
Investing Activities
PP&E Inv.-$0$0-$1-$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0-$35-$66
Inv. Sales/Matur.$19$58$44$0
Other Inv. Act.$0-$17-$0-$0
Investing Cash Flow$18$41$8-$66
Financing Activities
Debt Repay.-$0-$26-$25$25
Stock Issued$2$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$54-$0
Financing Cash Flow$2-$25$0$25
Forex Effect-$1$1-$0$0
Net Chg. in Cash-$15-$50-$26-$95
Supplemental Information
Beg. Cash$43$93$119$215
End Cash$28$43$93$119
Free Cash Flow-$35-$67-$35-$55
Adaptimmune Therapeutics plc (ADAP) Financial Statements & Key Stats | AlphaPilot